CABG patients with LV dysfunction should be pre- scribed -blocker therapy (bisoprolol, sustained- release metoprolol succinate, or carvedilol), unless contraindicated (Class I; Level of Evidence B). 4. Chronic -blocker therapy for hypertension treat- ment after CABG (in the absence of prior MI or LV dysfunction) may be considered, but other antihy- pertensive therapies may be more effective and more easily tolerated (Class IIb; Level of Evidence B). Hypertension Management Hypertension is a common antecedent condition before CABG, occurring in as many as 80% of patients.212 The preop- erative antihypertensive regimens used in patients undergoing CABG can be quite varied but generally include a -blocker or an ACE inhibitor, in part because of their cardioprotective Despite the routine use of these drug classes, however, pre-CABG and post-CABG BP control remains Previous AHA guidelines recommended a BP goal of <130/80 mmHg for patients with CAD.216 More recent guideline statements have proposed less aggressive BP target mmHg) for patients with CAD risk factors such as diabetes mellitus and chronic kid- ney disease. This is a controversial subject. Inconsistent ben- efits have been noted in clinical trials comparing intensive BP reduction (systolic <130 mmHg) and standard BP treatment goals (systolic <140 mmHg) for patients with previous coro- nary events and a history of hypertension and diabetes mel- litus, therefore justifying the currently recommended systolic target value of <140 mmHg.220 225 With regard to diastolic BP goals, targeting a value of <85 mmHg appears to be safe and has been shown in 3 randomized trials to improve the clinical outcomes of patients with a history of hypertension, diabe- tes mellitus, or multiple cardiovascular risk factors compared with higher diastolic values.226 228 Admittedly, no clinical trials to date have specifically assessed BP targets after CABG with respect to clinical outcomes. 